Literature DB >> 25964491

Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.

Ganesh E Phad1, Néstor Vázquez Bernat1, Yu Feng2, Jidnyasa Ingale2, Paola Andrea Martinez Murillo1, Sijy O'Dell3, Yuxing Li4, John R Mascola3, Christopher Sundling5, Richard T Wyatt2, Gunilla B Karlsson Hedestam6.   

Abstract

Isolation of mAbs elicited by vaccination provides opportunities to define the development of effective immunity. Ab responses elicited by current HIV-1 envelope glycoprotein (Env) immunogens display narrow neutralizing activity with limited capacity to block infection by tier 2 viruses. Intense work in the field suggests that improved Env immunogens are forthcoming, and it is therefore important to concurrently develop approaches to investigate the quality of vaccine-elicited responses at a higher level of resolution. In this study, we cloned a representative set of mAbs elicited by a model Env immunogen in rhesus macaques and comprehensively characterized their genetic and functional properties. The mAbs were genetically diverse, even within groups of Abs targeting the same subregion of Env, consistent with a highly polyclonal response. mAbs directed against two subdeterminants of Env, the CD4 binding site and V region 3, could in part account for the neutralizing activity observed in the plasma of the animal from which they were cloned, demonstrating the power of mAb isolation for a detailed understanding of the elicited response. Finally, through comparative analyses of mAb binding and neutralizing capacity of HIV-1 using matched Envs, we demonstrate complex relationships between epitope recognition and accessibility, highlighting the protective quaternary packing of the HIV-1 spike relative to vaccine-induced mAbs.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964491      PMCID: PMC4458414          DOI: 10.4049/jimmunol.1500122

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

3.  Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting.

Authors:  Christopher Sundling; Paola Martinez; Martina Soldemo; Mats Spångberg; Karin Lövgren Bengtsson; Linda Stertman; Mattias N E Forsell; Gunilla B Karlsson Hedestam
Journal:  J Infect Dis       Date:  2012-11-16       Impact factor: 5.226

4.  High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Authors:  Christopher Sundling; Yuxing Li; Nick Huynh; Christian Poulsen; Richard Wilson; Sijy O'Dell; Yu Feng; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Sci Transl Med       Date:  2012-07-11       Impact factor: 17.956

5.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

6.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

8.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  21 in total

Review 1.  Germline-targeting immunogens.

Authors:  Leonidas Stamatatos; Marie Pancera; Andrew T McGuire
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 2.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

3.  HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Authors:  Yimeng Wang; Sijy O'Dell; Hannah L Turner; Chi-I Chiang; Lin Lei; Javier Guenaga; Richard Wilson; Paola Martinez-Murillo; Nicole Doria-Rose; Andrew B Ward; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam; Yuxing Li
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

4.  Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.

Authors:  Navid Madani; Amy M Princiotto; David Easterhoff; Todd Bradley; Kan Luo; Wilton B Williams; Hua-Xin Liao; M Anthony Moody; Ganesh E Phad; Néstor Vázquez Bernat; Bruno Melillo; Sampa Santra; Amos B Smith; Gunilla B Karlsson Hedestam; Barton Haynes; Joseph Sodroski
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

5.  Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.

Authors:  David A Spencer; Delphine C Malherbe; Néstor Vázquez Bernat; Monika Ádori; Benjamin Goldberg; Nicholas Dambrauskas; Heidi Henderson; Shilpi Pandey; Tracy Cheever; Philip Barnette; William F Sutton; Margaret E Ackerman; James J Kobie; D Noah Sather; Gunilla B Karlsson Hedestam; Nancy L Haigwood; Ann J Hessell
Journal:  J Immunol       Date:  2021-01-20       Impact factor: 5.422

6.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

7.  Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.

Authors:  Cody S Nelson; Justin Pollara; Erika L Kunz; Thomas L Jeffries; Ryan Duffy; Charles Beck; Lisa Stamper; Minyue Wang; Xiaoying Shen; David J Pickup; Herman F Staats; Michael G Hudgens; Thomas B Kepler; David C Montefiori; M Anthony Moody; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari; Genevieve G A Fouda; Sallie R Permar
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

Review 8.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.

Authors:  Steven W de Taeye; John P Moore; Rogier W Sanders
Journal:  Trends Immunol       Date:  2016-02-09       Impact factor: 16.687

Review 9.  Harnessing the protective potential of HIV-1 neutralizing antibodies.

Authors:  S Abigail Smith; Cynthia A Derdeyn
Journal:  F1000Res       Date:  2016-01-05

10.  Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.

Authors:  Laura E McCoy; Marit J van Gils; Gabriel Ozorowski; Terrence Messmer; Bryan Briney; James E Voss; Daniel W Kulp; Matthew S Macauley; Devin Sok; Matthias Pauthner; Sergey Menis; Christopher A Cottrell; Jonathan L Torres; Jessica Hsueh; William R Schief; Ian A Wilson; Andrew B Ward; Rogier W Sanders; Dennis R Burton
Journal:  Cell Rep       Date:  2016-08-18       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.